Despite Generic Erosion of Key Brands, the Hospital-Acquired Gram Negative Infections Drug Market Will Increase by $1 Billion from 20...(eport forecasts that in 2018 generic ero...),Health

The report also finds that drug development for gram-negative infections has been slow and overshadowed by interest and investment in developing novel therapies for the more lucrative market of hospital-acquired infections due to gram-positive pathogens, namely, methicillin-resistant Staphylococcus aureus (MRSA). However, as competition increases and opportunities decline in the market for hospital-acquired infections due to MRSA, the hospital-acquired gram-negative infections market segment is ripe with attractive drug development opportunities.

"Competition between agents is relatively low in the hospital-acquired gram-negative infections market when compared with the market for hospital-acquired infections due to gram-positive pathogens," said Decision Resources Analyst Hemali Patel, Ph.D. "Minimal competition in the late-stage pipeline and high unmet need will allow novel agents with clearly demonstrated efficacy against key gram-negative pathogens to command a high price and favorable formulary position -- two key attributes that underlie commercial success in this market."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decisio
'/>"/>